Today, NorInvent was informed that the European Patent Office that the EPO had communicated an Intention to grant, which means that the patent will be granted in Europe.

NorInvent develops XtriG, the Company’s patented Drug Delivery platform for pharmaceutical uptake via the oral mucosa. XtriG aims at providing pharmaceutical companies with a means to give their existing drugs enhanced properties, such as significantly faster onset, reduced environmental impact and reduced dosage compared to peroral drug administration (swallowing of pills).

Today, the announcement was received that the EPO has communicated an Intention to grant. This means that the EPO will grant the patent in Europe. In addition, NorInvent has previously granted patents in seven countries; Sweden, Israel, Japan, Canada, China, Russia and South Korea, a Notice of Allowance for the patent in the United States, as well as an ongoing application in Brazil.

This information is information that NorInvent AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Paul Hasselgren (CEO, NorInvent AB), at 09:20 CET on March 16, 2018.

___________________________________
For additional information contact:
NorInvent AB (publ), CEO, Paul Hasselgren, telephone: +46 760 49 40 90
www.norinvent.com